investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
TGFB-SMAD Signaling in Stem Cell Differentiation and Tumor Suppression
Joan Massague
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Joan Massague
Memorial Sloan Kettering Cancer Center
New York, United States
Related projects
Thomas P Quinn
In vivo Metal-Free Cycloaddition Chemistry Driven Pretargeted Cancer Radiotherapy
Colorectum
Radiation Oncology
Needs Assessment to Assess Barriers to Developing a Comprehensive Cancer Center in LMICs
Breast
Philip N Tsichlis
The role of IWS1 in development and tumorigenesis
Breast
Sendurai A Mani
Pleiotropic Functions of FOXC2 in EMT, Stem Cells and Breast Cancer Progression
Breast
Sparreboom Alexander
Solute Carriers and Oxaliplatin Neurotoxicity
Colorectum
Pathology
Powel Brown
ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast
Yuet Ming Rebecca Chin
Akt isoform-specific signaling in breast cancer metastasis
Breast
Joe W Gray
Model-based Predictions of Responses RTK Pathway Therapies
Breast